Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Schlemmer

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Pediatric Blood & Cancer|March 28, 2009
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinibKatherine A Janeway, Karen H Albritton, Annick D Van Den Abbeele, et al.
Oncology Research and Treatment|September 25, 2019
Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant SettingPeter Reichardt, Marcus Schlemmer, Juan R Delgado Perez, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2006
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursMaria Debiec-Rychter, Raf Sciot, Axel Le Cesne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group studyMartine Van Glabbeke, Jaap Verweij, Paolo G Casali, et al.
European Journal of Cancer (Oxford, England : 1990)|April 14, 2011
Gastrointestinal stromal tumours in children and young adults: a clinicopathologic series with long-term follow-up from the database of the Cooperative Weichteilsarkom Studiengruppe (CWS)Martin Benesch, Ivo Leuschner, Eva Wardelmann, et al.
JAMA Oncology|March 24, 2017
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical TrialHeikki Joensuu, Eva Wardelmann, Harri Sihto, et al.
Clinical Genitourinary Cancer|December 12, 2018
Imaging in Suspected Renal-Cell Carcinoma: Systematic ReviewChristina Vogel, Brigitte Ziegelmüller, Börje Ljungberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized TrialHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Cancer|April 17, 2014
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinibHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
JAMA|March 29, 2012
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trialHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Pediatric Blood & Cancer|March 28, 2009
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinibKatherine A Janeway, Karen H Albritton, Annick D Van Den Abbeele, et al.
Oncology Research and Treatment|September 25, 2019
Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant SettingPeter Reichardt, Marcus Schlemmer, Juan R Delgado Perez, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2006
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursMaria Debiec-Rychter, Raf Sciot, Axel Le Cesne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group studyMartine Van Glabbeke, Jaap Verweij, Paolo G Casali, et al.
European Journal of Cancer (Oxford, England : 1990)|April 14, 2011
Gastrointestinal stromal tumours in children and young adults: a clinicopathologic series with long-term follow-up from the database of the Cooperative Weichteilsarkom Studiengruppe (CWS)Martin Benesch, Ivo Leuschner, Eva Wardelmann, et al.
JAMA Oncology|March 24, 2017
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical TrialHeikki Joensuu, Eva Wardelmann, Harri Sihto, et al.
Clinical Genitourinary Cancer|December 12, 2018
Imaging in Suspected Renal-Cell Carcinoma: Systematic ReviewChristina Vogel, Brigitte Ziegelmüller, Börje Ljungberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized TrialHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Cancer|April 17, 2014
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinibHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
JAMA|March 29, 2012
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trialHeikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Pageof 3